Table 1.
Baseline characteristics by APR levels
| |
Neither APR elevated |
APR levels discordant |
Both APR elevated |
P
value |
|---|---|---|---|---|
| n = 2,520 | n = 1,058 | n = 650 | ||
| Age (years) |
59.29 ± 13.22 |
62.21 ± 13.21 |
62.71 ± 13.34 |
<0.0001 |
| Duration of RA (years) |
11.01 ± 9.83 |
11.93 ± 10.68 |
10.91 ± 10.27 |
0.0406 |
| One-year follow-up duration (days) |
362.63 ± 30.51 |
363.33 ± 31.06 |
363.46 ± 32.03 |
0.7410 |
| mHAQ |
0.33 ± 0.40 |
0.45 ± 0.47 |
0.56 ± 0.54 |
<0.0001 |
| CDAI |
12.89 ± 10.15 |
15.18 ± 11.16 |
20.47 ± 14.68 |
<0.0001 |
| Tender joints |
3.73 ± 5.24 |
4.29 ± 5.40 |
6.30 ± 7.21 |
<0.0001* |
| Swollen joints |
4.04 ± 5.13 |
4.80 ± 5.49 |
6.64 ± 6.42 |
<0.0001* |
| Patient global assessment |
30.91 ± 23.82 |
36.35 ± 25.45 |
42.90 ± 27.56 |
<0.0001 |
| MD global assessment |
20.21 ± 16.61 |
24.67 ± 19.06 |
32.42 ± 22.50 |
<0.0001 |
| Prednisone use |
680 (26.98%) |
341 (32.23%) |
275 (42.31%) |
<0.0001 |
| Methotrexate use |
1,668 (66.19%) |
698 (65.97%) |
417 (64.15%) |
0.6166 |
| Biologic use | 1,263 (50.12%) | 447 (42.25%) | 224 (34.46%) | <0.0001 |
*Log-linear model (Poisson) - χ2 test. APR, acute phase reactant; RA, rheumatoid arthritis; mHAQ, modified Health Assessment Questionnaire; CDAI, Clinical Disease Activity Index.